You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Laparoscopic Middle hepatic vein Hepatocellular carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Chongqing (laparoscopic middle hepatic vein guidance anatomic hemihepatectomy)

Recruiting
  • Hepatocellular Carcinoma
  • laparoscopic middle hepatic vein guidance anatomic hemihepatectomy
  • Chongqing, Chongqing, China
    Southwest Hospital
Jan 13, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Hepatic artery infusion chemo(HAIC), Durvalumab)

Recruiting
  • Hepatocellular Carcinoma
  • Hepatic artery infusion chemotherapy（HAIC）
  • Durvalumab
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
May 18, 2022

Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • I-125 Seeds Brachytherapy in PVTT
  • +2 more
  • (no location specified)
Aug 14, 2023

Hepatic Carcinoma, Hepatic Metastasis Trial in Pamplona (Octreotide, Placebo)

Recruiting
  • Hepatic Carcinoma
  • Hepatic Metastasis
  • Pamplona, Spain
    Clinica Universidad de Navarra
Oct 10, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 4, 2023

HepatoCellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Sorafenib)

Completed
  • HepatoCellular Carcinoma
  • Portal Vein Thrombosis
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Oct 8, 2021

Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Lenvatinib 1, Camrelizumab 1)

Recruiting
  • Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • HAIC
  • +4 more
  • Beijing, Beijing, China
    Peking Univerisity Cancer Hospital
Jan 10, 2022

Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Camrelizumab, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • FOLFOX-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jan 19, 2022

End Stage Liver Disease, Acute Liver Failure, Acute-On-Chronic Liver Failure Trial in Riyadh (Donor hepatectomy)

Enrolling by invitation
  • End Stage Liver Disease
  • +3 more
  • Donor hepatectomy
  • Riyadh, Saudi Arabia
    Organ Transplant Center of Excellence, King Faisal Specialist Ho
Sep 28, 2023

Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer Trial in Milan (Embolization)

Recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • Embolization
  • Milan, Italy
    IRCCS Ospedale San Raffaele
Feb 3, 2023

Hepatocellular Carcinoma With Major Portal Vein Thrombosis Trial (HAIC (Hepatic arterial infusion chemo), HLX10 (PD-1 antibody),

Not yet recruiting
  • Hepatocellular Carcinoma With Major Portal Vein Thrombosis
  • HAIC (Hepatic arterial infusion chemotherapy)
  • +3 more
  • (no location specified)
Jun 24, 2021

Liver Cancer Trial in Guanzhou (PD1/PDL1 inhibitor)

Unknown status
  • Liver Cancer
  • PD1/PDL1 inhibitor
  • Guanzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Apr 4, 2021

Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)

Unknown status
  • Carcinoma, Hepatocellular
  • +3 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020

Hepatocellular Cancer Trial in Shanghai (hepatic resection, Sorafenib)

Recruiting
  • Hepatocellular Cancer
  • Shanghai, China
    Eastern Hepatobiliary Surgery Hospital
Apr 8, 2021

Primary Hepatocellular Carcinoma, Portal Vein Thrombosis Trial (Recombinant human adenovirus type 5 + TACE)

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • Recombinant human adenovirus type 5 + TACE
  • (no location specified)
May 14, 2023

Hepatocellular Carcinoma Trial in Hangzhou (PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • PVE+cTACE+Camrelizumab+Apatinib
  • cTACE+Atirizumab+Bevacizumab
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Feb 26, 2023

Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Portal Hypertension
  • TACE ± Systemic therapy
  • Nanjing, China
  • +1 more
Jan 28, 2023

Hepatocellular Carcinoma Trial in Shanghai (laparoscopic hepatectomy, Open hepatectomy)

Active, not recruiting
  • Hepatocellular Carcinoma
  • laparoscopic hepatectomy
  • Open hepatectomy
  • Shanghai, China
    Huashan hospital
Aug 16, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 24, 2023

Hepatocellular Carcinoma Trial (HAIC(FOLFOX), Oxaliplatin, Leucovorin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • HAIC(FOLFOX)
  • +5 more
  • (no location specified)
Aug 16, 2022

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma Trial in Chongqing (Laparoscopic Hepatectomy, Radiofrequency Ablation)

Completed
  • Hepatocellular Carcinoma
  • Laparoscopic Hepatectomy
  • Radiofrequency Ablation
  • Chongqing, Chongqing, China
    JianChen
May 29, 2022

Postoperative Outcomes in Chinese HCC Patients Treated With

Recruiting
  • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Aug 1, 2023

    C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou, Guanzhou, Changsha (Hepatic Arterial Infusion

    Recruiting
    • C-staged Hepatocellular Carcinoma in BCLC Classification
    • Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
    • Apatinib combined with Camrelizumab
    • Guangzhou, Guangdong, China
    • +4 more
    Jun 15, 2022

    TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

    Completed
    • Hepatocellular Carcinoma
    • TACE-HAIC
    • +3 more
    • GuangZhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 8, 2022